{"id":54219,"date":"2026-01-15T16:28:01","date_gmt":"2026-01-15T08:28:01","guid":{"rendered":"https:\/\/flcube.com\/?p=54219"},"modified":"2026-01-15T16:28:02","modified_gmt":"2026-01-15T08:28:02","slug":"exegenesis-bio-files-for-hong-kong-ipo-with-ai-powered-gene-therapy-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=54219","title":{"rendered":"Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline"},"content":{"rendered":"\n<p><strong>Exegenesis Bio Inc.<\/strong>, a gene therapy developer founded in 2019, filed for a listing on the <strong>Hong Kong Stock Exchange<\/strong> (HKEX), seeking to raise approximately <strong>USD 150\u2011200\u202fmillion<\/strong> to advance its AI\u2011enhanced pipeline targeting <strong>spinal muscular atrophy (SMA) and ocular diseases<\/strong>. The company leverages proprietary platforms <strong>AAVarta<\/strong> and <strong>SODA<\/strong> to develop next\u2011generation gene therapies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ipo-milestone\">IPO Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Exegenesis Bio Inc.<\/td><\/tr><tr><td><strong>Filing Venue<\/strong><\/td><td>Hong Kong Stock Exchange (HKEX)<\/td><\/tr><tr><td><strong>Filing Date<\/strong><\/td><td>08\u202fJan\u202f2026<\/td><\/tr><tr><td><strong>Founded<\/strong><\/td><td>2019<\/td><\/tr><tr><td><strong>Headquarters<\/strong><\/td><td>Hangzhou, China<\/td><\/tr><tr><td><strong>Estimated IPO Proceeds<\/strong><\/td><td>USD <strong>150\u2011200\u202fmillion<\/strong><\/td><\/tr><tr><td><strong>Use of Proceeds<\/strong><\/td><td>60\u202f% for clinical trials, 25\u202f% for platform expansion, 15\u202f% for working capital<\/td><\/tr><tr><td><strong>Lead Underwriters<\/strong><\/td><td><strong>Goldman Sachs<\/strong>, <strong>J.P. Morgan<\/strong>, <strong>CICC<\/strong> (estimated)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-platforms\">Technology Platforms<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-aavarta-ai-assisted-aav-capsid-evolution\"><strong>AAVarta \u2013 AI-Assisted AAV Capsid Evolution<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Function:<\/strong> Proprietary AAV capsid discovery platform using <strong>machine learning<\/strong> to engineer novel serotypes with <strong>enhanced tissue tropism<\/strong> and <strong>reduced immunogenicity<\/strong><\/li>\n\n\n\n<li><strong>Innovation:<\/strong> <strong>In silico<\/strong> prediction of capsid variants followed by <strong>high\u2011throughput in vivo screening<\/strong>; reduces discovery timeline from <strong>36\u202fmonths to 12\u202fmonths<\/strong><\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-soda-silencing-oligonucleotide-design-approach\"><strong>SODA \u2013 Silencing Oligonucleotide Design Approach<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Function:<\/strong> AI\u2011driven design of <strong>antisense oligonucleotides (ASOs)<\/strong> and <strong>siRNAs<\/strong> for target knockdown<\/li>\n\n\n\n<li><strong>Advantage:<\/strong> Optimizes <strong>chemical modifications<\/strong>, <strong>delivery vectors<\/strong>, and <strong>off\u2011target profiling<\/strong> simultaneously<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-pipeline\">Clinical Pipeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Candidate<\/th><th>Technology<\/th><th>Indication<\/th><th>Stage<\/th><th>Key Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>EXG001-307<\/strong><\/td><td>AAV\u2011based gene therapy<\/td><td><strong>SMA Type 1<\/strong><\/td><td>Pre\u2011IND \/ IND\u2011enabling<\/td><td>Potential <strong>best\u2011in\u2011class<\/strong> vs. Zolgensma; lower vector dose, reduced liver toxicity<\/td><\/tr><tr><td><strong>EXG102-031<\/strong><\/td><td>AAV\u2011based gene therapy<\/td><td><strong>wAMD<\/strong> (wet age\u2011related macular degeneration)<\/td><td>Preclinical<\/td><td>Single\u2011 injection vs. monthly anti\u2011VEGF injections; sustained efficacy<\/td><\/tr><tr><td><strong>EXG202<\/strong><\/td><td>AAV\u2011based gene therapy<\/td><td><strong>Ocular neovascular diseases<\/strong> (wAMD, DME, RVO)<\/td><td>Discovery<\/td><td><strong>Pan\u2011ocular platform<\/strong> targeting multiple retinal indications<\/td><\/tr><tr><td><strong>7 Additional Assets<\/strong><\/td><td>Gene therapy \/ oligonucleotide<\/td><td>Various oncology\/rare diseases<\/td><td>Discovery \/ Preclinical<\/td><td>Diversified pipeline leveraging dual platforms<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity\">Market Opportunity<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Indication<\/th><th>Global Market Size (2026E)<\/th><th>Target Population<\/th><th>Competitive Landscape<\/th><\/tr><\/thead><tbody><tr><td><strong>SMA Type 1<\/strong><\/td><td>$2.8\u202fbillion<\/td><td>~1,200 new cases\/year (US\/EU\/China)<\/td><td>Novartis Zolgensma ($2.1M\/dose), Roche Evrysdi (oral)<\/td><\/tr><tr><td><strong>wAMD<\/strong><\/td><td>$11.6\u202fbillion<\/td><td>20\u202fmillion patients globally<\/td><td>Regenxbio, Adverum (gene therapy); Eylea, Lucentis (anti\u2011VEGF)<\/td><\/tr><tr><td><strong>DME \/ RVO<\/strong><\/td><td>$7.2\u202fbillion<\/td><td>10\u202fmillion+ patients<\/td><td>Same anti\u2011VEGF competitors; no approved gene therapies<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-amp-strategic-positioning\">Financial &amp; Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Valuation:<\/strong> Pre\u2011money estimated at <strong>USD 500\u2011600\u202fmillion<\/strong> based on comparable AI\u2011gene therapy companies<\/li>\n\n\n\n<li><strong>Revenue Model:<\/strong> Near\u2011term <strong>partnership revenues<\/strong> (platform licensing); long\u2011term <strong>product sales<\/strong> and <strong>milestones<\/strong><\/li>\n\n\n\n<li><strong>Investor Base:<\/strong> <strong>Viva Biotech<\/strong> (incubator) remains largest shareholder; new investors include <strong>Hong Kong\u2011based family offices<\/strong> and <strong>biotech crossover funds<\/strong><\/li>\n\n\n\n<li><strong>Manufacturing:<\/strong> In\u2011house GMP facility in Hangzhou (2,000L scale) for AAV production; capacity for <strong>clinical supply through Phase\u202fII<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-advantages\">Competitive Advantages<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>AAVarta Platform:<\/strong> Novel capsids show <strong>5\u2011fold higher retinal transduction<\/strong> and <strong>3\u2011fold lower liver sequestration<\/strong> vs. AAV2\/AAV8 in preclinical models<\/li>\n\n\n\n<li><strong>Integrated AI:<\/strong> <strong>SODA platform<\/strong> reduces oligonucleotide design cycles from <strong>6\u202fmonths to 8\u202fweeks<\/strong><\/li>\n\n\n\n<li><strong>Cost Efficiency:<\/strong> In\u2011house manufacturing reduces COGS by <strong>40%<\/strong> vs. CDMO model<\/li>\n\n\n\n<li><strong>Diversification:<\/strong> Dual platform (gene therapy + oligonucleotide) mitigates <strong>AAV immunogenicity<\/strong> risks<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Exegenesis Bio\u2019s IPO timeline, valuation, and pipeline advancement. Actual results may differ due to market conditions, regulatory review timelines, and competitive dynamics in gene therapy.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Exegenesis Bio Inc., a gene therapy developer founded in 2019, filed for a listing on&#8230;<\/p>\n","protected":false},"author":1,"featured_media":54221,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2153,72],"class_list":["post-54219","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-exegenesis-bio","tag-ipo"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Exegenesis Bio Inc., a gene therapy developer founded in 2019, filed for a listing on the Hong Kong Stock Exchange (HKEX), seeking to raise approximately USD 150\u2011200\u202fmillion to advance its AI\u2011enhanced pipeline targeting spinal muscular atrophy (SMA) and ocular diseases. The company leverages proprietary platforms AAVarta and SODA to develop next\u2011generation gene therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=54219\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline\" \/>\n<meta property=\"og:description\" content=\"Exegenesis Bio Inc., a gene therapy developer founded in 2019, filed for a listing on the Hong Kong Stock Exchange (HKEX), seeking to raise approximately USD 150\u2011200\u202fmillion to advance its AI\u2011enhanced pipeline targeting spinal muscular atrophy (SMA) and ocular diseases. The company leverages proprietary platforms AAVarta and SODA to develop next\u2011generation gene therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=54219\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-15T08:28:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-15T08:28:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1504.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54219#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54219\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline\",\"datePublished\":\"2026-01-15T08:28:01+00:00\",\"dateModified\":\"2026-01-15T08:28:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54219\"},\"wordCount\":499,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54219#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1504.webp\",\"keywords\":[\"Exegenesis Bio\",\"IPO\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54219#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54219\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=54219\",\"name\":\"Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54219#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54219#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1504.webp\",\"datePublished\":\"2026-01-15T08:28:01+00:00\",\"dateModified\":\"2026-01-15T08:28:02+00:00\",\"description\":\"Exegenesis Bio Inc., a gene therapy developer founded in 2019, filed for a listing on the Hong Kong Stock Exchange (HKEX), seeking to raise approximately USD 150\u2011200\u202fmillion to advance its AI\u2011enhanced pipeline targeting spinal muscular atrophy (SMA) and ocular diseases. The company leverages proprietary platforms AAVarta and SODA to develop next\u2011generation gene therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54219#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54219\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54219#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1504.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1504.webp\",\"width\":1080,\"height\":608,\"caption\":\"Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54219#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"Exegenesis Bio Inc., a gene therapy developer founded in 2019, filed for a listing on the Hong Kong Stock Exchange (HKEX), seeking to raise approximately USD 150\u2011200\u202fmillion to advance its AI\u2011enhanced pipeline targeting spinal muscular atrophy (SMA) and ocular diseases. The company leverages proprietary platforms AAVarta and SODA to develop next\u2011generation gene therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=54219","og_locale":"en_US","og_type":"article","og_title":"Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline","og_description":"Exegenesis Bio Inc., a gene therapy developer founded in 2019, filed for a listing on the Hong Kong Stock Exchange (HKEX), seeking to raise approximately USD 150\u2011200\u202fmillion to advance its AI\u2011enhanced pipeline targeting spinal muscular atrophy (SMA) and ocular diseases. The company leverages proprietary platforms AAVarta and SODA to develop next\u2011generation gene therapies.","og_url":"https:\/\/flcube.com\/?p=54219","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-15T08:28:01+00:00","article_modified_time":"2026-01-15T08:28:02+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1504.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=54219#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=54219"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline","datePublished":"2026-01-15T08:28:01+00:00","dateModified":"2026-01-15T08:28:02+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=54219"},"wordCount":499,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=54219#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1504.webp","keywords":["Exegenesis Bio","IPO"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=54219#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=54219","url":"https:\/\/flcube.com\/?p=54219","name":"Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=54219#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=54219#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1504.webp","datePublished":"2026-01-15T08:28:01+00:00","dateModified":"2026-01-15T08:28:02+00:00","description":"Exegenesis Bio Inc., a gene therapy developer founded in 2019, filed for a listing on the Hong Kong Stock Exchange (HKEX), seeking to raise approximately USD 150\u2011200\u202fmillion to advance its AI\u2011enhanced pipeline targeting spinal muscular atrophy (SMA) and ocular diseases. The company leverages proprietary platforms AAVarta and SODA to develop next\u2011generation gene therapies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=54219#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=54219"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=54219#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1504.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1504.webp","width":1080,"height":608,"caption":"Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=54219#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1504.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54219","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=54219"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54219\/revisions"}],"predecessor-version":[{"id":54222,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54219\/revisions\/54222"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/54221"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=54219"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=54219"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=54219"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}